



The Canadian Association for Population Therapeutics presents:

**“Knowledge to Provide Evidence
for Health Care Decision-Makers:
Clinical Practice and Research Methodology”**

PROGRAM

April 17th – 19th, 2011

Ottawa, Ontario

The Westin Hotel

CAPT MISSION & VISION

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

CAPT 2011 SCIENTIFIC PROGRAM COMMITTEE:

Anick Bérard, University of Montreal (Co-Chair)
Sylvie Perreault, University of Montreal (Co-Chair)
Lucie Blais, University of Montreal
Daria O'Reilly, PATH - McMaster University
Mohsen Sadatsafavi, University of British Columbia
Lori-Jean Manness, Merck Canada Inc.
Michael Iskedjian, PharmIdeas
Durhane Wong-Rieger, Consumer Advocare Network
Christoph Laer
Valencia Remple, Pfizer Canada Inc.
Julie Villeneuve, Sanofi-Aventis Canada Inc.
Fei Fei Liu, Eli Lilly Canada Inc.
Mary De Vera, University of Montreal

CAPT 2011 LOCAL ORGANIZING COMMITTEE:

Denis Belanger, CADTH (Co-Chair)
Marie-Anik Gagne, Health Canada (Co-Chair)
Frances Hall, Health Canada
Cynthia Sunstrum, Health Canada

www.capt-actp.com

“Knowledge to Provide Evidence for Health Care Decision-Makers: Clinical Practice and Research Methodology”

Message from the President

Welcome to the 2011 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! We are pleased to be in the nation's capital, as an organization uniquely addressing the needs of Canadians investigating population-based therapeutic research, policy and practice.

Nothing is constant but change; as a dynamic association, CAPT is adding new dimensions to our annual conference. For 2011, we are introducing pre-conference educational workshops, a professional showcase, a special-interest group abstract session and breakfast meeting, and a student dinner. On behalf of the board of CAPT, we hope you enjoy the conference and look forward to the next few days of learning, discussing, and connecting with colleagues.

Angela Rocchi
CAPT President

CAPT 2011 Conference Overview

Welcome to the 2011 CAPT/ACTP conference! The title of this year's conference, “Knowledge to Provide Evidence for Health Care Decision-Makers: Clinical Practice and Research Methodology,” speaks to the need to provide evidence on the results from clinical practice and research methods to support scientific evidence to health policy and decision-making. The Program Committee offers its sincere thanks to the sponsors who have made this conference possible.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists, by including more panel sessions than in previous conferences, and by balancing sessions in pharmacoepidemiology and health economics with others in health policy. This year for the first time, we have included introduction and advanced courses in pharmacoepidemiology and pharmacoconomics in the program, a professional showcase, and the Special Interest Group on Medications and Pregnancy will meet for the first time. Finally, we have many exciting contributed presentations and posters. We encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Anick Bérard & Sylvie Perreault
Co-Chairs, 2011 Scientific Program Committee

“Knowledge to Provide Evidence for Health Care Decision-Makers: Clinical Practice and Research Methodology”

Sunday, April 17th, 2011

07:15 – 17:00 Registration (Confederation Ballroom Foyer)

Pre-Conference Symposium

Location: Confederation I Ballroom

Chair: Anick Bérard, University of Montreal

08:00 – 10:00 Introduction to Pharmacoepidemiology
Fabiano Santos, University of Montreal

Introduction to Pharmacoeconomics
Karen Lee (Director), Canadian Agency for Drugs and
Technologies in Health

10:00 – 10:15 Coffee Break

10:15 – 12:15 Advanced Pharmacoepidemiology
Mary De Vera, University of Montreal
Lucie Blais (Professor), University of Montreal

12:00 – 13:00 Welcome Lunch (Provinces I, II Room)
(All conference registrants welcome)

Conference Commencement

Location: Confederation I Ballroom

13:00 – 13:15 Opening Remarks & Welcome
Angela Rocchi, Axia Research and President, CAPT

Issues Panel (13:15 – 16:00)

Sponsored by: AstraZeneca Canada

Providing Value for Decision-Makers: From Adaptive Design to Personalized Medicine

Chair: Nicole Mittmann, HOPE Research Centre

Sunday, April 17th, 2011

- 13:15 – 13:45** **Field of Cardiovascular Disease**
Simon Dedenus (Professor), University of Montreal
- 13:45 – 14:15** **Economics, Personalized Health Care and Cancer Control**
Stuart Peacock (Co-Director), Canadian Centre for Applied Research in Cancer Control (ARCC)
- 14:15 – 14:45** **Break & Contributed Poster Presentations**
Location: Confederation Foyer & Confederation Ballroom III
- 14:45 – 15:15** **Personalized Medicine and Considerations for Clinicians, Health Care Decision-Makers and Researchers**
Pending Speaker Confirmation
- 15:15 – 16:00** **Panel / Plenary Discussion**
- 16:00 – 17:00** **Contributed Oral Presentations**

Concurrent Session 1

Location: Confederation Ballroom I

Chair: Odile Sheehy, CHU Ste-Justine

From priorities to action: improving cardiovascular prevention in primary care
L Lalonde, University of Montreal (Abstract 8)

Association between use of antiretroviral therapy and risk of acute myocardial infarction: a nested case control study using Quebec's Public Health Insurance Database (RAMQ)
M Durand, University of Montreal (Abstract 2)

Streamlining drug coverage in Canada: An analysis of new drug products before and after the introduction of the Common Drug Review process
JM Gamble, University of Alberta (Abstract 18)

Documentation of human epidermal growth factor receptor-2 (HER2) testing and trastuzumab (TRA) treatment in Ontario breast cancer (BC) patients: a retrospective analysis
IL Ferrusi, Centre for Evaluation of Medicines, McMaster University (Abstract 7)

Concurrent Session 2

Location: Confederation Ballroom II

Chair: Jocelyne Moisan, Université Laval

Income-related inequity in drug treatment following acute myocardial infarction

GE Hanley, University of British Columbia (Abstract 11)

Health care costs of uncontrolled asthma: a population-based cohort study in British Columbia, 2002-2007

P Bedouch, University of British Columbia (Abstract 10)

Asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study

M Sadatsafavi, University of British Columbia (Abstract 3)

Generic drug pricing in Canada

J Lawson, SECORE Consulting; S Majumder, Health Council of Canada (Abstract 9)

17:00 – 18:15

Reception (Sponsored by Pfizer Canada) & Contributed Poster Presentations

Location: Confederation Foyer & Confederation Ballroom III

18:15 – 20:00

Pfizer Canada Symposium:

The Impact of Chronic Disease on the Labour Workforce

Location: Confederation I Ballroom

Objectives of the symposium:

1. To review the evidence in Canada and other countries around the impact of chronic disease on the labour force participation
2. To discuss the importance of obtaining valid data to determine and predict labour workforce trends due to chronic disease
3. To highlight the need to consider productivity, absenteeism and general workforce labour participation in epidemiological and health economic type studies in the context of an aging population context coupled with an increasing prevalence of chronic disease,
4. To identify potential solutions and new approaches to mitigate the impact of chronic disease on labour force participation

Sunday, April 17th, 2011

Chair: Philip Merrigan, Université du Québec à Montréal

Impact of Chronic Disease on Labour Force Participation in Canada

Philip Merrigan (Professor), Université du Québec à Montréal

The Impact of Chronic Diseases on Work Outcomes in the United States

Kimberly Jinnett (Research Director), Integrated Benefits Institute

Health and Wealth in Australia: The Impact of Chronic Disease on Labour Force Participation and the Economy

Rupendra Shrestha (Research Fellow), NHMRC Clinical Trials Centre, University of Sydney

Monday, April 18th, 2011

07:30 – 17:00 **Registration (Confederation Ballroom Foyer)**

07:30 – 08:30 **Breakfast (Provinces I, II Room)**

Keynote Speakers: Methods (08:30 – 11:30)

Location: Confederation I Ballroom

Chair: Lucie Blais, University of Montreal

08:30 – 09:30 **Biases Due to Frailty in Population Based Studies of Medical Interventions: Outline of the Problem and Methods to Address It**

Til Stürmer (Professor), UNC Gillings School of Global Public Health

09:30 – 10:15 **Research Synthesis: Review, Meta-analysis and Indirect Comparison**

George A. Wells (Professor), University of Ottawa

10:15 – 10:45 **Break, Contributed Poster Presentations & Professional Showcase**

Location: Foyer & Confederation Ballroom III

10:45 – 11:30 **Methods in Pharmacogenomics**

Marie-Pierre Dubé (Director of Statgen, Professor), University of Montreal

Monday, April 18th, 2011

11:30 – 13:00 **Lunch (Sponsored by Innovus) & Professional Showcase**
Location: Provinces I, II Room; Confederation Foyer

(The Professional Showcase will run from 10:15 to 17:00)

12:00 – 13:00 **CAPT Annual General Meeting**
Location: Confederation I Ballroom
All conference registrants are encouraged to attend

13:00 – 14:30 **Contributed Oral Presentations**

Concurrent Session 1: (SIG: Medications and Pregnancy)

Location: Confederation I Ballroom

Chair: Anick Bérard, University of Montreal

Medically assisted reproduction (MAR), including ovulation stimulators, and the risk of major congenital malformations: The AtRISK Study

S Chaabane, CHU Ste-Justine, University of Montreal (Abstract 14)

Influence of birth month on diagnosis and treatment of attention-deficit/hyperactivity disorder in school-age children

RL Morrow, University of British Columbia (Abstract 12)

Quality assessment of clinical practice guidelines for the prescription of antidepressant drugs during pregnancy

F Santos, CHU Ste-Justine, University of Montreal (Abstract 16)

Antidepressant use during pregnancy and the risk of gestational hypertension

MA De Vera, CHU Ste-Justine, University of Montreal (Abstract 1)

Beta-2-agonists use during pregnancy and the risk of congenital malformations

S Eltonsy, Hôpital du Sacré-Coeur de Montréal, University of Montreal, (Abstract 4)

Relapse of depression in pregnant users and discontinued users of antidepressants: results from the OTIS Antidepressants Study

A Bérard, CHU Ste-Justine, University of Montreal (Abstract 17)

Concurrent Session 2

Location: Confederation II Ballroom

Chair: Suzanne Cadarette, University of Toronto

Comparison of data from clinical trials versus small experimental studies for establishing the cognitive safety of anticholinergic drugs. A systematic review and meta-analysis using bladder antimuscarinic agents

C Tannenbaum, University of Montreal (Abstract 5)

Interventions to increase influenza and pneumococcal vaccinations in community-dwelling adults: a systematic review and meta-analysis

D Lau, University of Alberta (Abstract 13)

Denosumab is cost-effective in the treatment of high risk postmenopausal osteoporotic women in Canada

D Chau, Amgen Canada Inc. (Abstract 6)

The cost-utility and value of information of transcatheter aortic valve implantation compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic valve stenosis

B Doble, McMaster University, PATH Research Institute (Abstract 20)

Systematic review of low-molecular-weight heparins versus unfractionated heparin in chronic hemodialysis patients

N Burke, McMaster University, PATH Research Institute (Abstract 19)

Public opinions on physician-pharmaceutical industry interactions: a Canadian survey

AM Holbrook, McMaster University (Abstract 15)

Keynote Speaker: Drug Safety and Effectiveness Network (DSEN) Update

Location: Confederation I Ballroom

14:30 – 15:00

Drug Safety and Effectiveness Network (DSEN) Update

Robert Peterson (Executive Director), Drug Safety and Effectiveness Network

15:00 – 15:30

Break, Contributed Poster Presentations & Professional Showcase

Location: Confederation Foyer & Confederation Ballroom III

Monday, April 18th, 2011

Estimation of Benefit/Risk Methodology, and Building a Registry or Database (15:30 – 17:00)

Location: Confederation I Ballroom

Sponsored by: GlaxoSmithKline Canada

Chair: Lyne Lalonde, University of Montreal

- 15:30 – 16:15** **Global Registry of Acute Coronary Events (GRACE)**
Jan Kornder (General Cardiology Lead Physician), Fraser Health Authority
- 16:15 – 17:00** **Exploring the International Landscape of New Methods for Benefit-Risk Assessment**
Larry Lynd (Professor), University of British Columbia
- 17:00 – 19:00** **Cocktail Reception with Cash Bar**
Open to all CAPT Registrants and Partners
Location: Daly's Restaurant, The Westin Hotel
- 18:00 – 18:30** **Parliament Tour**
Departing from Daly's Restaurant at 17:30
- 19:00** **Student Dinner (open to CAPT student registrants only)**
Location: Métropolitain Brasserie, 700 Sussex Drive (Rideau Street and Sussex)

Departing from Daly's Restaurant at 18:45

Tuesday, April 19th, 2011

- 07:30 – 13:00** **Registration (Confederation Ballroom Foyer)**
- 07:30 – 08:30** **Breakfast (Provinces I, II Room)**

Tuesday, April 19th, 2011

07:30 – 08:30 **Special Interest Group Breakfast: Medications and Pregnancy**
Location: Governor General I Room

Sponsored by: Duchesnay Inc.

Chair: Anick Bérard, University of Montreal

Decisional Balance: How Can We Understand the Value of Innovative Medicines in the Midst of Scientific Uncertainty? (08:30 – 10:30)

Location: Confederation I Ballroom

Sponsored by: Merck Canada

Chair: Linda Levesque, Queen's University

08:30 – 09:00 **Innovative Medicines: Opportunities and Challenges to Improve Research and Health Care Decision Makers Expectations?**

Brian White-Guay (Professor), University of Montreal

09:00 – 09:30 **Going Beyond Effectiveness and Cost-Effectiveness: How Can We Identify And Incorporate Other Important Factors for Healthcare Decision-Making?**

Ron Goeree (Professor), McMaster University

09:30 – 10:00 **Establishing the Value of Innovative Medicines While Dealing with Uncertainty Using Multi-Criteria Decision Analysis (MCDA)**

Mireille Goetghebeur (President), BioMedCom

10:00 – 10:30 **Plenary Discussion**

10:30 – 11:00 **Break**

Location: Confederation Foyer

The Future of Medicines Regulations (11:00 – 12:30)

Location: Confederation I Ballroom

Sponsored by: sanofi-aventis Canada

Chair: Sylvie Perreault, University of Montreal

11:00 – 11:45 **Where Does Pharmacoepidemiology Fit into Evaluation of Benefit/Risk and Comparative Effectiveness**
Bruno Flamion (Professor), University of Namur, Former Chair of the Scientific Advice Working Party, EMA/CHMP

11:45 – 12:15 **Future Medicines: Regulations, Decision Makers and Patient Concerns**
Brian White-Guay (Professor), University of Montreal

12:15 – 13:15 **Lunch**
Sponsored by: Amgen Canada

Hot Topic: Biologic Agents (13:15 – 15:15)
Location: Confederation I Ballroom

Chair: Adrian Levy, Dalhousie University

13:15 – 13:35 **View on Benefit/Safety**
Claire Bombardier (Professor), University of Toronto

13:35 – 13:55 **View of the Patient**
Stephanie Marcovitch (Executive Director), Ontario Gastrointestinal Society

13:55 – 14:15 **View of Health Technology Assessment and Advice for Decision-Makers**
Robert Peterson (Executive Director), Drug Safety and Effectiveness Network

14:15 – 14:35 **View of the Industry**
Peter Brenders (President and CEO), BIOTECanada

14:35 – 14:55 **View of the Payer (Private)**
Suzanne Lepage (Private Health Plan Strategist), Suzanne Lepage Consulting

14:55 – 15:15 **Discussion**

15:15 – 15:30 **CAPT Awards Ceremony / Conference Close**
Anick Bérard, Incoming CAPT President

ORAL PRESENTATIONS

(Note: Presenting Authors are underlined)

- 1
De Vera MA, Hanley G, Oberlander T, Koren G, Rey E, St-Andre M, Bérard A **Antidepressant use during pregnancy and the risk of gestational hypertension**
- 2
Durand M, Sheehy O, Lelorier J, Tremblay CL **Association between use of antiretroviral therapy and risk of acute myocardial infarction: a nested case control study using Quebec's Public Health Insurance Database (RAMQ)**
- 3
Sadatsafavi M, Bedouch P, FitzGerald JM, Marra CA, Lynd LD **Asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study**
- 4
Eltonsy S, Forget A, Blais L **Beta-2-agonists use during pregnancy and the risk of congenital malformations**
- 5
Tannenbaum C, Paquette A **Comparison of data from clinical trials versus small experimental studies for establishing the cognitive safety of anticholinergic drugs. A systematic review and meta-analysis using bladder antimuscarinic agents**
- 6
Chau D, Coombes M, Becker D, Marshall D, Goeree, R, Ioannidis G **Denosumab is cost-effective in the treatment of high risk postmenopausal osteoporotic women in Canada**
- 7
Ferrusi IL, Trudeau M, Earle C, Leigh N, Cascagnette P, Pullenayegum E, Hoch J, Marshall DA **Documentation of human epidermal growth factor receptor-2 (HER2) testing and trastuzumab (TRA) treatment in Ontario breast cancer (BC) patients: a retrospective analysis**
- 8
Lalonde L, Lévesque L, Hudon É, Goudreau J, Bareil C, Lussier M-T, Duhamel F, Bélanger D **From priorities to action: improving cardiovascular prevention in primary care**
- 9
Abbott J, Lawson J, Griller D, Majumder S **Generic drug pricing in Canada**
- 10
Bedouch P, Sadatsafavi M, FitzGerald JM, Marra CA, Lynd LD **Health care costs of uncontrolled asthma: a population-based cohort study in British Columbia, 2002-2007**
- 11
Hanley GE, Morgan S, Reid RJ **Income-related inequity in drug treatment following acute myocardial infarction**
- 12
Morrow RL, Garland EJ, Wright JM, Maclure M, Taylor S, Dormuth CR **Influence of birth month on diagnosis and treatment of attention-deficit/hyperactivity disorder in school-age children**

13

Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA **Interventions to increase influenza and pneumococcal vaccinations in community-dwelling adults: a systematic review and meta-analysis**

14

Chaabane S, Sheehy O, Blais L, Fraser W, Bissonnette F, Désilets V **Medically assisted reproduction (MAR), including ovulation stimulators, and the risk of major congenital malformations: The AtRISK Study**

15

Holbrook AM, Lexchin J, Willison D, Pullenayegum E, Troyan S, Campbell C, Marlow B, Weijer C, Blackmer J, Brazil K **Public opinions on physician-pharmaceutical industry interactions: a Canadian survey**

16

Santos F, Sola I, Rigau D, Arevalo-Rodriguez I, Seron P, Alonso-Coello P, Berard A, Bonfill X **Quality assessment of clinical practice guidelines for the prescription of antidepressant drugs during pregnancy**

17

Berard A, Karam F, Sheehy O, Huneau MC, Blais L, Briggs G, Roth M, Chambers C, Einarson A, Gaedigk A, Riordan SH, Johnson D, Kao K, Koren G, Martin BZ, Polifka JE, Voyer Lavigne S, Wolfe L, and the OTIS Collaborative Research **Relapse of depression in pregnant users and discontinued users of antidepressants: results from the OTIS Antidepressants Study**

18

Gamble JM, Weir DL, Johnson JA, Eurich DT **Streamlining drug coverage in Canada: An analysis of new drug products before and after the introduction of the Common Drug Review process**

19

Burke N, Tarride J-E, Bowen JM, von Keyserlingk C, Lim W, Crowther M, Goeree R **Systematic review of low-molecular-weight heparins versus unfractionated heparin in chronic hemodialysis patients**

20

Doble B, Perampaladas K, von Keyserlingk C, Campbell K, Blackhouse G, Goeree R, Xie F **The cost-utility and value of information of transcatheter aortic valve implantation compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic valve stenosis**

POSTER PRESENTATIONS

21

Yang M, Rajan S, Issa AM **A cost-effectiveness analysis of two commercially available gene expression profiling tests: implications for reimbursement decision-making and policy**

22

Soon JA, Wiens MO, MacLeod SM **An environmental scan of graduate training programs in Canadian Universities able to train post-market drug safety and effectiveness researchers**

23

Kasmani A, Clifford T, Coyle D, Kelly S **Assessing the prognostic value of technetium-99m in coronary artery disease screening with myocardial perfusion imaging in asymptomatic patients with type 2 diabetes: a systematic review, economic evaluation and policy analysis**

24

Rance L, Hwang P **Association of co-payments with compliance and employee sick days/short-term disability (ACCESS): The ACCESS Study**

25

Cribb N, Merali T, Donato BMK **Canadian chronic phase chronic myeloid leukemia (CP-CML) treatment patterns and clinical outcomes study**

26

Hunt J, Gaucher M **Canadian public drug program spending on seniors, 2002 to 2008**

27

Hunt J, Gaucher M **Number and type of drugs used by seniors on public drug programs in Canada, 2002 to 2008**

28

Marrie J, McDonald H **Challenges in the economic evaluation of topical anti-rosacea agents: an illustration using azelaic acid**

29 - ENCORE PRESENTATION

Bremner KE, Tomlinson G, Luo J, Alibhai SMH, Krahn MD **Changing patterns of androgen deprivation therapy use in prostate cancer patients in Ontario from 1995 to 2005**

30

Rocchi A, Miller E, Hopkins R, Goeree R **Common Drug Review recommendations: analysis of predictors**

31

Pettigrew M, Deuson R, Garces K **Comparative net cost impact of the utilization of Nplate® (romiplostim) and Intravenous Immunoglobulin (IVig) for the treatment of patients with Immune Thrombocytopenia (ITP) in Ontario**

32

Guertin JR, Dorais M, Sauriol L, Matteau A, Poulin F, Khairy P, LeLorier J **Comparison of amiodarone-treated to antiarrhythmic naïve elderly patients with atrial fibrillation: an observational study**

33

Richard-Tremblay AA, Sheehy O, Audibert F, Ferreira E, Bérard A **Concordance between preconceptional and periconceptional vitamin/folic acid supplementation and the joint SOGC-MOTHERISK clinical guidelines**

34

Tarride J-E, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R **Cost Effectiveness Analysis of Intranasal Live Attenuated (LAIV) versus Injectable Inactivated (TIV) Influenza Vaccine for Canadian Children and Adolescents**

35

Tarride J-E, Harrington K, Balfour R, Simpson P, Foord L, Anderson L, Lakey WH **Evaluation of a workplace health program for British Columbia public service agency (Canada) - an example of partnership in employee health**

36

Tarride J-E, Hopkins R, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, Brown JP, Goeree R **The burden of illness of osteoporosis in Canada**

37

Redding L, Hornberger J, Cowens W, Chien R, Wang M **Cost-effectiveness of febuxostat in managing Hyperuricemia in gout patients in Canada**

38 - ENCORE PRESENTATION

Beard K, Folia C, Liovas A **Currently available platelet function tests are highly variable when used to identify patients who are resistant to clopidogrel**

39

Tony M, Goetghebeur MM, Khoury H, Wagner M, Battista R, Deal CL **Decisionmaking for rare diseases: developing evidence-based clinical practice guidelines for growth hormone therapy in Prader-Willi syndrome using the EVIDEM framework**

40

Holbrook AM, Keshavjee K, Troyan S, for COMPETE Catalyst Team **Designing a National eHealth Drug Safety and Effectiveness Research Network**

41

Gregoire J-P, Breton M-C, Moisan J **Determinants of adherence to antidiabetes treatment among newly treated patients with oral antidiabetes drugs**

42

Dragomir A, Tarride J-E, Angers J-F, Joobor R, Rouleau GA, Perreault S **Direct cost of schizophrenia in Quebec, Canada: an incidence-based microsimulation monte-carlo markov model**

43

Perreault S, Yu A, Côté R, Dragomir A **Effectiveness of Adherence to Antihypertensive Agents after Ischemic Stroke**

44

Laliberté MC, Perreault S, Jouini G, Shea BJ, Lalonde L **Effectiveness of interventions to improve the detection and treatment of osteoporosis in primary care settings: a systematic review and meta-analysis**

45

Beard K, Ng V **Estimating the cost effectiveness of ramipril in the prevention of new diagnoses of type 2 diabetes**

46

Kawasumi Y, Cunningham C, Hanley G, So L, Law M, Morgan S **Ethnic variation in the quality of asthma management in British Columbia**

47

Richler D, Chin W **Generic comparators - what is the best approach?**

48

Leung VWY, Soon JA, Marra CA, Lynd LD, Levine M **History of regular hormonal contraceptive use among emergency contraceptive users in British Columbia**

49 - ENCORE PRESENTATION

Scobie AC, Boyle T, MacKinnon NJ, Mahaffey T **Impact of process characteristics on quality related event reporting in Nova Scotia community pharmacies**

50

Durand M, Sheehy O, Lelorier J, Baril J-G, Tremblay CL **Increased risk of Intra-cranial hemorrhage in HIV infected subjects is mainly due to AIDS and comorbidities: a population-based study**

51

Hamdi H, Moisan J, Grégoire J-P **Initiation of ACE inhibitors and angiotensin receptor blockers in elderly patients taking oral antidiabetes drugs**

52 - ENCORE PRESENTATION

Morgan S, Cunningham C, Law M **Innovation deficit or imitation deficit in drug development?**

53

Colmers IN, Bowker SL, Johnson JA **Insulin and cancer outcomes in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies**

54

Karam F, Sheehy O, Huneau MC, Briggs G, Roth M, Chambers C, Einarson A, Riordan SH, Johnson D, Kao K, Koren G, Martin BZ, Polifka JE, Voyer Lavigne S, Wolfe L, Bérard A and the OTIS Research Committee **Maternal prenatal and parental postnatal stress in a cohort of depressed women and their partners**

55

Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Sauriol L, Villeneuve J **Modelling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis**

56

Cadarette SM, Baek D, Gunraj N, Carney G, Paterson JM, Dormuth CR **Patterns of osteoporosis medication prescribing in British Columbia and Ontario, 1995/96-2008/09: impact of public drug coverage**

57

Turgeon M, Guénette L, Tremblay E, Gaudet M **Persistence to antidepressants and quality of their use in adults diagnosed with major depression in Quebec: a cohort study from 2005 to 2009**

58

Guénette L, Mintzes B **Pharmaceutical sales representatives' activities in Canada, France and the U.S.: opinions of key stakeholders on the effectiveness of current regulatory practices**

59

Al Hamarneh YN, Charrois TL, Lewanczuk RZ, Tsuyuki RT **Pharmacist intervention for glycemic control in the community (The RxING Study)**

60

Jouini G, Choinière M, Martin E, Perreault S, Berbiche D, Lussier D, Lalonde L **Pharmacotherapeutic management of chronic non-cancer pain in primary care**

61

Wiktorowicz M, Lexchin J, Majumder S **Post-market surveillance of drug safety and effectiveness: international approaches and lessons for Canada**

62

Laroche ML, Bongué B, Gutton S, Guéguen R, Merle L **Potentially inappropriate prescribing in the elderly from the EGB database in France**

63

Lalonde L, Choiniere M, Martin E, Belanger D, Perreault S, Hudon E, Lacasse A, Duhamel F **Programme ACCORD: Priorities for action to improve the management of patients with non-cancer chronic pain (NCCP) in primary care (PC)**

64

Ferrusi IL, Leigh N, Kulin NA, Marshall DA **Providing Evidence to inform decision making: do economic evaluations of targeted therapy follow economic evaluation (EE) guidelines?**

65

Legris ME, Charbonneau-Séguin N, Desforges K, Sauvé P, Lord A, Bell R, Berbiche D, Desrochers JF, Lemieux JP, Morin-Bélanger C, Ste-Marie F, [Lalonde L](#) **Quality of medication use in chronic kidney disease patients: development and pilot testing of a web-based training program for community pharmacists**

66

Desrochers JF, Lemieux JP, Morin-Bélanger C, Ste-Marie Paradis F, Lord A, Bell R, Berbiche D, Charbonneau-Séguin N, Desforges K, Legris ME, Sauvé P, [Lalonde L](#) **Quality of medication use in chronic kidney disease patients: development and validation of the pair criteria**

67

[Daw JR](#), Orr K, Morgan SG **Stitching the gaps in the Canadian drug coverage patchwork: have provincial pharmacare policies converged towards a national standard?**

68

Jordan J, [Breckles J](#), Leung V **Sustained cost savings and fewer dose administration errors in hemodialysis patients converted from epoetin alfa to darbepoetin alfa in a community hospital setting**

69

Dourdin N, Wagner M, [Melnyk P](#), Rindress D **Systematic review to assess the quality of published health economic evaluations**

70

[Santos E](#), Sheehy O, Perreault S, Ferreira E, Bérard A **Trends in anti-infective drugs use during pregnancy in Canada**

71

Semchuk W, [Levac BA](#), Shakespeare A, Evers T **Understanding treatment gaps in warfarin management of stroke prevention in atrial fibrillation**

72

[Bérard A](#), Sheehy O, Fraser W, Bissonnette F, Tan SL, Trasler J, Monnier P **Use of ovulation stimulation (OS) alone, intrauterine insemination (IUI) and assisted reproductive techniques (ART) and the risk of multiplicity - The TWINPREG Study**

73

[Currie L](#), MacPherson K, Flowerdew G, Bilski P, Bethune G, Sketris I **Utilization of drugs and the risk of falls in a long term care facility**

74

[Soon JA](#), Leung VWY, Levine M, Reade JA, Shoveller JA **Utilization of regular contraceptives among rural northern youth in British Columbia: an ethnographic study**

75

[Marin-Leblanc M](#), Perreault S, Bahroun I, Lapointe M, Mongrain I, Provost S, Turgeon J, Talajic M, Brugada R, Phillips M, Tardif JC, Dubé MP **Validation of warfarin pharmacogenetic algorithms in real clinical practice**

76

[Maclure M](#), Madigan D, Fireman B, Nelson JL, Morrow R, Dormuth C, Schneeweiss S **When can self-controlled crossover studies of only cases be used for rapid pharmacosurveillance?**

PLATINUM

**AstraZeneca Canada Inc.
GlaxoSmithKline Inc.
Merck Canada Inc.
Pfizer Canada Inc.
Sanofi-Aventis**

GOLD

**Amgen Canada Inc.
Duchesnay
Innovus**

SILVER

**Abbott Canada
Applied Management
Axia Research
Bayer Canada
Canada's Research-Based Pharmaceutical Companies (Rx&D)
Cornerstone Research
Hoffmann-La Roche
Institute of Health Economics
Novartis Pharma
Nycomed Canada Inc.
Statsciences**

BRONZE

**Astellas Pharma
Paladin Labs
PharmIdeas
Purdue Pharma
Servier Canada**